DRKS00021006招募中不适用
Safety and Effectiveness of teduglutide (Revestive ®) treatment in paediatric patients with chronic intestinal failure due to short bowel syndrome – an observational study - TEDU-REG
Klinik für Kinder- und JugendmedizinUniversitätsklinikum Ulm0 个研究点目标入组 40 人开始时间: 2020年3月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 1 Years 至 18 Years（—）
- 性别
- All
入选标准
- •Children 1 to 18 years of age receiving treatment with Revestive® in Germany and Austria according to the drug license
- •Signed informed consent from parents or legal representative
排除标准
- •Missing signed consent and off-label use
研究者
相似试验
进行中（未招募）
1 期
A Study of the Safety and Efficacy of Teduglutide in Subjects with Parenteral Nutrition-Dependant Short Bowel Syndrome Who Completed Protocol CL0600-004 - N/AEUCTR2004-000439-27-DKPS Allelix Corporation80
进行中（未招募）
不适用
A study of the Efficacy and Safety of Teduglutide in subjects with Parenteral Nutritional Dependant Short Bowel Syndrome - N/AEUCTR2004-000438-35-DKPS Allelix Corporation125
已完成
不适用
A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in CanadaShort Bowel Syndrome (SBS)NCT05371028Takeda52
招募中
Unknown
Expert Opinion on the Proper Use of Teduglutide as Treatment for Short Bowel Syndrome in Adult Patientsshort bowel syndromeJPRN-UMIN000052594Takeda Pharmaceutical Company Limited10
已完成
3 期
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel SyndromeShort Bowel SyndromeNCT00081458Shire84